OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500
Debt
Debt-to-Equity Ratio0.57
Current Ratio9.66
Quick Ratio9.50
Price-To-Earnings
Trailing P/E Ratio-2.61
Forward P/E Ratio-4.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$47.50 million
Price / Sales12.73
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book3.59
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees82
Outstanding Shares41,220,000
Market Cap$797.38 million
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) released its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.64) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.13. The business earned $1.27 million during the quarter, compared to analyst estimates of $1.01 million. View OptiNose's Earnings History.
When is OptiNose's next earnings date?
What price target have analysts set for OPTN?
5 equities research analysts have issued twelve-month price targets for OptiNose's stock. Their forecasts range from $27.00 to $33.00. On average, they anticipate OptiNose's stock price to reach $29.60 in the next twelve months. This suggests a possible upside of 101.8% from the stock's current price. View Analyst Price Targets for OptiNose.
What is the consensus analysts' recommendation for OptiNose?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.
What are Wall Street analysts saying about OptiNose stock?
Here are some recent quotes from research analysts about OptiNose stock:
- 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (8/15/2018)
- 2. Cantor Fitzgerald analysts commented, ": We are initiating research coverage of OPTN stock with an Overweight rating and 12-month PT of $30. We view Xhance as an asset that will create significant share value and allow the company to expand commercial activities into ENT- and allergist-managed medical conditions. We believe OPTN should be able to leverage the proprietary exhalation delivery system (EDS) to develop therapies that fit within the target physician population and could be applicable for other medical uses that could create partnering/out-licensing opportunities." (8/7/2018)
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT) and Myokardia (MYOK).
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 57)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres& COO (Age 53)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 42)
- Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)
When did OptiNose IPO?
(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.
Has OptiNose been receiving favorable news coverage?
Media stories about OPTN stock have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. OptiNose earned a coverage optimism score of 0.14 on Accern's scale. They also assigned news stories about the company an impact score of 46.64 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for OptiNose.
Who are OptiNose's major shareholders?
OptiNose's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (16.09%), BlackRock Inc. (2.62%), Waddell & Reed Financial Inc. (1.93%), Massachusetts Financial Services Co. MA (1.85%), Wells Fargo & Company MN (1.19%) and Kornitzer Capital Management Inc. KS (0.93%). Company insiders that own OptiNose stock include Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.
Which major investors are selling OptiNose stock?
Which major investors are buying OptiNose stock?
OPTN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Waddell & Reed Financial Inc., Rice Hall James & Associates LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, State of New Jersey Common Pension Fund D and American Century Companies Inc.. Company insiders that have bought OptiNose stock in the last two years include Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $14.67.
How big of a company is OptiNose?
OptiNose has a market capitalization of $797.38 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (NASDAQ OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
